Trinity Biotech plc (TRIB)
TRIB Stock Price Chart
Explore Trinity Biotech plc interactive price chart. Choose custom timeframes to analyze TRIB price movements and trends.
TRIB Company Profile
Discover essential business fundamentals and corporate details for Trinity Biotech plc (TRIB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
21 Oct 1992
Employees
380.00
Website
https://www.trinitybiotech.comCEO
John Gillard
Description
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
TRIB Financial Timeline
Browse a chronological timeline of Trinity Biotech plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Apr 2026
Upcoming earnings on 17 Sept 2025
EPS estimate is -$2.55.
Stock split effective on 27 Aug 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Jul 2025
EPS came in at -$2.40 falling short of the estimated -$0.28 by -757.14%.
Earnings released on 15 May 2025
EPS came in at -$1.02 falling short of the estimated -$0.30 by -240.00%, while revenue for the quarter reached $15.86M , missing expectations by -0.89%.
Earnings released on 29 Jan 2025
EPS came in at -$0.06 surpassing the estimated -$0.54 by +88.92%, while revenue for the quarter reached $15.86M .
Earnings released on 15 Nov 2024
EPS came in at -$0.43 surpassing the estimated -$0.54 by +20.37%, while revenue for the quarter reached $15.15M , missing expectations by -8.17%.
Earnings released on 1 Oct 2024
EPS came in at $1.00 surpassing the estimated -$0.65 by +253.85%, while revenue for the quarter reached $15.84M .
Earnings released on 23 May 2024
EPS came in at -$0.37 surpassing the estimated -$3.00 by +87.67%, while revenue for the quarter reached $13.43M , missing expectations by -8.51%.
Earnings released on 4 Apr 2024
EPS came in at -$0.68 surpassing the estimated -$3.50 by +80.57%, while revenue for the quarter reached $14.70M , beating expectations by +0.18%.
Stock split effective on 23 Feb 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 3 Oct 2023
EPS came in at -$1.00 falling short of the estimated -$0.09 by -1.01K%, while revenue for the quarter reached $14.68M , beating expectations by +1.22%.
Earnings released on 6 Sept 2023
EPS came in at -$0.06 , while revenue for the quarter reached $19.50M .
Earnings released on 6 Jul 2023
EPS came in at -$0.80 falling short of the estimated -$0.06 by -1.23K%, while revenue for the quarter reached $13.90M , beating expectations by +2.95%.
Earnings released on 23 Mar 2023
EPS came in at -$0.90 falling short of the estimated -$0.06 by -1.40K%, while revenue for the quarter reached $14.83M , missing expectations by -17.78%.
Earnings released on 15 Dec 2022
EPS came in at -$0.90 falling short of the estimated -$0.20 by -350.00%, while revenue for the quarter reached $18.04M , beating expectations by +0.20%.
Earnings released on 30 Jun 2022
EPS came in at -$0.40 falling short of the estimated -$0.20 by -100.00%, while revenue for the quarter reached $18.46M , missing expectations by -7.68%.
Earnings released on 11 Apr 2022
EPS came in at $0.30 surpassing the estimated $0.07 by +328.57%, while revenue for the quarter reached $18.78M , missing expectations by -21.77%.
Earnings released on 31 Dec 2021
EPS came in at $0.02 , while revenue for the quarter reached $19.53M .
Earnings released on 15 Dec 2021
EPS came in at $0.45 , while revenue for the quarter reached $22.00M , missing expectations by -11.98%.
Earnings released on 9 Sept 2021
EPS came in at $1.00 surpassing the estimated $0.07 by +1.33K%, while revenue for the quarter reached $25.84M .
Earnings released on 25 May 2021
EPS came in at $0.50 surpassing the estimated $0.07 by +614.29%, while revenue for the quarter reached $25.59M , beating expectations by +6.64%.
Earnings released on 30 Apr 2021
EPS came in at -$0.09 , while revenue for the quarter reached $32.77M .
Earnings released on 17 Nov 2020
EPS came in at $1.80 surpassing the estimated $0.10 by +1.70K%, while revenue for the quarter reached $32.01M , missing expectations by -16.67%.
TRIB Stock Performance
Access detailed TRIB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.